Items Tagged ‘Rectal Cancer’

October 16th, 2017

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

By

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in […]

View full entry

Tags: BRAF, Colon Cancer, erbitux, News, Precision Cancer Medicine, Rectal Cancer, V600E, vemurafenib, zelboraf


September 18th, 2017

NSAIDs Decrease Risk of Colorectal Cancer

By

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively relieve pain, inflammation, and fever.  A number of treatment guidelines for osteoarthritis, rheumatoid arthritis, and chronic low back pain recommend the use of NSAIDs […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer


March 6th, 2017

Proton Beam Therapy may Improve Outcomes for Rectal Cancer

By

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause […]

View full entry

Tags: News, proton beam therapy, Rectal Cancer


July 28th, 2016

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

By

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to […]

View full entry

Tags: 5fu, Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, crc, dmmr, eloxatin, mismatch repair, News, oxaliplatin, Rectal Cancer, Stages I-III Rectal Cancer


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


May 9th, 2016

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers

By

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent report supports the results of previous clinical studies that have also demonstrated that the daily use of aspirin reduces the risk of death from several common cancers, including lung, […]

View full entry

Tags: aspirin, benefit, cancer, Colon Cancer, colorectal, daily, Esophageal Cancer, gastrointestinal, lung, Lung Cancer, News, Rectal Cancer


May 2nd, 2016

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection

By

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing colorectal cancer who choose not to undergo other colorectal cancer screening methods specified in […]

View full entry

Tags: approval, Colon Cancer, colorectal cancer, EPI proColon, fda, News, non-invasive, Rectal Cancer, risk, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


March 4th, 2016

Anesthesia Increases Colonoscopy Risks

By

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the large intestine (colon) for signs of cancer, abnormal areas that could turn into cancer, […]

View full entry

Tags: Anal Cancer, anesthesia, Colon Cancer, colonoscope, colonoscopy, News, Rectal Cancer, risks, Screening/Prevention Anal Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

By

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe […]

View full entry

Tags: Anal Cancer, Breast Cancer, capecitabine, Colon Cancer, fda, fluorouracil, Gastric Cancer, Gastrointestinal Stromal Tumors, life-threatening, Liver Cancer, News, Pancreatic Cancer


February 3rd, 2016

Colorectal Cancer: Year in Review

By

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has been done with combination therapies and protocols for treatment. Of great importance, research shows that when colorectal cancer is detected during a screening colonoscopy, patients […]

View full entry

Tags: Colon Cancer, News, Rectal Cancer


January 28th, 2016

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing

By

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, KRAS exon 2, News, panitumumab, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, Stages I-III Rectal Cancer, vectibix


November 16th, 2015

Does Processed Meat Cause Colorectal Cancer?

By

According to the International Agency for Research on Cancer (IARC), eating processed meat products can increase a person’s risk for developing colorectal cancer. Processed meat is classified as meat that has been salted, cured, fermented, or smoked to add flavor or preserve the meat. These meats include ham, bacon, sausages, corned beef, hot dogs, canned […]

View full entry

Tags: Colon Cancer, News, prevention, processed meat, Rectal Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


September 30th, 2015

Lonsurf® Approved for the Treatment of Colorectal Cancer

By

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although death rates from colorectal cancer have declined in the past 10 years which is thought to be due […]

View full entry

Tags: advanced, Colon Cancer, colorectal cancer, fda, Lonsurf, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, tipiracil, trifluridine


August 24th, 2015

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing

By

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at multiple sites. Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established […]

View full entry

Tags: advanced colorectal cancer, clinical trail, Colon Cancer, News, Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xilonix